ATDBio has been sold to Biotage

ATDBio is a leader in oligonucleotide synthesis. Based in Oxford and Southampton, UK, the company’s expertise is in highly complex DNA and RNA production with work in molecular diagnostics, drug discovery, nucleic acid-based therapeutics and vaccines plus new generation DNA and RNA sequencing technologies. ATDBio was founded in 2005 by Professor Tom Brown Sr., one of the world’s leading nucleic acids chemists.

The company’s attention to detail, combined with years of experience and a knowledge of the latest developments in nucleic acids chemistry, enables it to provide an unrivalled service. ATDBio works with both academic groups and high profile pharmaceutical and biotechnology companies worldwide.

ATDBio’s expertise will provide Biotage, a global impact technology company based in Sweden, with market access and know-how in the rapidly growing DNA and RNA oligonucleotide sector while broadening its chemical modality platforms and portfolio offering.

Lincoln acted as the exclusive financial advisor to ATDBio, working closely with the shareholders throughout the sale process.

ATDBio Boitage 2021
  • 2021
    Close Year
  • Healthcare | Industrials
    Industry
  • Private
    Client Type
  • Strategic | Cross-border
    Transaction Type
  • Sweden | United Kingdom
    Countries
I am grateful to the Lincoln team for providing strategic guidance and valuable advice throughout the process, delivering an excellent outcome for ATDBio’s shareholders.
Dr. Tom Brown Jr.
Director of ATDBio

Meet our Senior Team